TCR-T治疗与CAR-T同属于T细胞治疗，但TCR-T治疗的靶标反应范围更加广泛，被视作对抗实体战场上的超级利刃，蕴藏着巨大潜力!极度令人振奋，TCR-T治疗创新地开辟出一条“一箭双雕”的神奇治疗之路，同时向和病毒感染发起猛烈攻击时，行动拿出了高效的、安全性与有效的正因如此，近几年来，研究人员尝试将TCR-T治疗对...
TCR-T治疗与CAR-T同属于T细胞治疗,但TCR-T治疗的靶标反应范围更加广泛,被视作对抗实体战场上的超级利刃,蕴藏着巨大潜力!极度令人振奋,TCR-T治疗创新地开辟出一条“一箭双雕”的神奇治疗之路,同时向和病毒感染发起猛烈攻击时,行动拿出...
Pan Q, et al. Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A∗02:01 patients with advanced soft tissue sarcoma. Cell Rep Med. 2023 Aug 15;4(8):101133.Ishihara M, et al. NY-ESO-1-specific redirected T cells with endogenous TCR kn...
lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 2011; 29: 917-924 Pan, Q., et al. Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A∗02:01 patients with advanced soft tissue sarcoma. Cell Reports Medicine, 2023,4(8), 101133.
最后,通过动物肿瘤模型验证抗原特异性高亲和力TCR-T对肿瘤生长的抑制作用。在获得高亲和力和非特异性TCR基因后,使用慢病毒作为载体,将识别肿瘤相关抗原NY-ESO-1的高亲和力TCR基因转移到患者自身的T细胞中,并将其回输给患者,以治愈肿瘤患者或终生效果。 T细胞毒性T淋巴细胞是体内主要的抗CD8细胞毒性T细胞(CTL),CTL主...
Pan Q, et al. Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A∗02:01 patients with advanced soft tissue sarcoma. Cell Rep Med. 2023 Aug 15;4(8):101133. Ishihara M, et al. NY-ESO-1-specific redirected T cells with endogenous TCR ...
TCR T cells bear virally infected T cell receptors for targeting antigen-bearing tumor cells. NY-ESO-1-specific T cell receptor (TCR) T cells can target GBM cells. Decitabine (DAC) increases NY-ESO-1 expression, specifically in CSCs, potentially enabling the eradication of this cell ...
Carl June and colleagues report the results of a phase I/II trial of adoptively transferred engineered T cells in patients with advanced multiple myeloma. Despite recent therapeutic advances, multiple myeloma (MM) remains largely incurable. Here we repor
T细胞免疫治疗主要包括CAR-T(Chimeric Antigen Receptor T cells, CAR-T)和TCR-T (T Cell Receptor,TCR)。CAR-T细胞治疗目前在血液肿瘤取得良好的治疗效果,然而对实体肿瘤的治疗效果并不十分理想。经过基因改造的TCR可结合MHC递呈的细胞内部抗原,因此TCR-T可以识别缺少特异性膜抗原的肿瘤细胞。此外与CAR-T相比,TCR...
patients (80%) with advanced disease, with a median progression-free survival of 19.1 months. NY-ESO-1–LAGE-1 TCR–engineered T cells were safe, trafficked to marrow and showed extended persistence that correlated with clinical activity against antigen-positive myeloma. ...